Advancing Science, Rooted in History

Azalla Pharma draws its name from the ancient Sumerian term “a·zal·la.” The related Syrian term “azal,” meaning “to spin,” symbolizes the transformation and advancement of modern medicine.

At Azalla Pharma, we honor this legacy by redefining it through modern science. By pioneering synthetic small molecule therapies inspired by nature’s complexity, we are setting a new benchmark for pharmaceutical innovation, addressing critical unmet medical needs in inflammation and neuroinflammation.

Azalla Pharma is a preclinical-stage pharmaceutical company dedicated to developing synthetic small molecule therapies for neuroinflammatory diseases. By integrating the wisdom of traditional medicine with the precision of modern science, we are positioned as a leader in the development of transformative, scalable therapies.

From Discovery to Innovation

Azalla Pharma is advancing a novel class of synthetic compounds with potent anti-inflammatory properties. Our lead candidates, Juva-019 and Juva-041, represent a breakthrough in therapeutic innovation. These synthetic small molecules are:

Potent: Demonstrating significant inhibition of key inflammatory cytokines, including TNF-alpha, IL-1B, and IL-10, in gold-standard in vitro and in vivo models.
Safe: Exhibiting low toxicity and exceptional tolerability across rigorous preclinical studies.
Precise: Engineered to replicate the therapeutic potential of natural while eliminating the need for plant-derived extracts.

By focusing on the specific pathways responsible for anti-inflammatory effects, Azalla Pharma is pioneering a new class of disease-modifying, orally available therapies to address neuroinflammation, and other inflammatory conditions through an innovative, chemistry-driven approach.